Accidental intravenous injections of BioNTech jabs may cause heart muscle inflammation, research conducted by the University of Hong Kong has found.
And so the recent reports from Israel’s Ministry of Health caught my eye. In early July, they reported that efficacy against infection and symptomatic disease “fell to 64%.” By late July it had fallen to 39% where Delta is the dominant strain. This is very low. For context, the FDA’s expectation is of “at least 50%” efficacy for any approvable vaccine.
Now Israel, which almost exclusively used Pfizer vaccine, has begun administering a third “booster” dose to all adults over 40. And starting 20 September 2021, the US plans to follow suit for all “fully vaccinated” adults eight months past their second dose.
And it’s hard to imagine how the Delta variant could play a real role here, for 77% of trial participants were from the United States, where Delta was not established until months after data cut-off.
Until new clinical trials demonstrate that boosters increase efficacy above 50%, without increasing serious adverse events, it is unclear whether the 2-dose series would even meet the FDA’s approval standard at six or nine months.
Daj jih še ti za hec.Khm, poglej moja zadnja dva posta.
IJS: Se ukvarjamo z atomsko fiziko, v prostem času pa napovedujemo razvoj epidemije.Ta isti IJS, ki je ze prej povsem mimo ustrelil? Do petka je pa res jaka muda "napovedovati".
A lahko nehaš lagati ker te bom prijavil zaradi obrekovanja.Je že na prejšni strani. Da on ga je kupil iz indije za 55usd s poštnino in tako povzročil kaznivo dejanje.
Abstract:
mRNA-based vaccines provide effective protection against most common SARS-CoV-2 variants.
However, identifying likely breakthrough variants is critical for future vaccine development. Here,
we found that the Delta variant completely escaped from anti-N-terminal domain (NTD)
neutralizing antibodies, while increasing responsiveness to anti-NTD infectivity-enhancing
antibodies. Although Pfizer-BioNTech BNT162b2-immune sera neutralized the Delta variant,
when four common mutations were introduced into the receptor binding domain (RBD) of the
Delta variant (Delta 4+), some BNT162b2-immune sera lost neutralizing activity and enhanced the
infectivity. Unique mutations in the Delta NTD were involved in the enhanced infectivity by the
BNT162b2-immune sera. Sera of mice immunized by Delta spike, but not wild-type spike,
consistently neutralized the Delta 4+ variant without enhancing infectivity. Given the fact that a
Delta variant with three similar RBD mutations has already emerged according to the GISAID
database, it is necessary to develop vaccines that protect against such complete breakthrough
variants.
O fak. Si res to napisu? Ti pa si zglajzal. Si že komentiral svoje limanje zavajujočih posnetkov, ki niso imeli nobene povezave s cepljenjem? Pazi da tebe ne prijavimo zaradi očitnega zavajanja.A lahko nehaš lagati ker te bom prijavil zaradi obrekovanja.
Torej drži to, kar sem pred kratkim polinkal, da je učinkovitost Pfizerjevega cepiva po 6 mesecih proti Delta sevu le še 36%. Karkoli pod 50% pa pade izven EUA odobritve - očitno že po 4 mesecih, po tvojih podatkih.Najnovejša Pfizerjeva študija o njihovem cepivu in o učunkovitosti (> 3 mio cepljenih).
Par povzetkov:
- bolj kakor delta sama ima vpliv pojemajoča imunost zaradi cepiv, prvi mesec zaščita 88 %, po petih mesecih pade na 47 %.
- pri delti je zaščita prvi mesec 93 %, že po 4 mesecih pade na 53 % (samo za občutek, interval zaupanja je 39 % - 65 %)
Findings: For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95%CI: 72‒74) and against COVID-19-related hospitalizations was 90% (89‒92). Effectiveness against infections declined from 88% (86‒89) during the first month after full vaccination to 47% (43‒51) after ≥5 months. Among sequenced infections, VE against Delta was lower compared to VE against other variants (75% [71‒78] vs 91% [88‒92]). VE against Delta infections was high during the first month after full vaccination (93% [85‒97]) but declined to 53% [39‒65] at ≥4 months. VE against hospitalization for Delta for all ages was high overall (93%).
Poglej priponko 47914Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study
Background: Vaccine effectiveness (VE) studies have not differentiated the impact of Delta from potential waning immunity on recent observed reductions in effecpapers.ssrn.com
No, bo kaj? Cepijo otroke na silo al si mal zabluzil?